Heterocyclic biphen-3-yl carboxamide derivatives as STAT6 inhibitors for the treatment of allergic or inflammatory diseases
A novel biaryl compound with a heteroaryl or oxo-substituted substituent addresses the lack of effective STAT6 inhibitors by providing a therapeutic solution for inflammatory and allergic diseases, notably atopic dermatitis and bronchial asthma.
WO2026116503A1PCT designated stage Publication Date: 2026-06-04KAKEN PHARMA CO LTD +1
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- KAKEN PHARMA CO LTD
- Filing Date
- 2025-11-28
- Publication Date
- 2026-06-04
AI Technical Summary
Technical Problem
Current treatments for inflammatory and allergic diseases, such as atopic dermatitis and bronchial asthma, do not effectively inhibit the activation and function of STAT6, a key mediator in IL-4 and IL-13 signaling, despite the potential therapeutic benefits suggested by STAT6 knockout models and decoy oligonucleotide studies.
Method used
Development of a novel biaryl compound with a heteroaryl group or oxo-substituted substituent at the 4-position, which exhibits a potent STAT6 inhibitory effect, providing a pharmaceutical agent for treating these diseases.
Benefits of technology
The compound effectively inhibits STAT6 activation, offering therapeutic benefits for allergic and inflammatory diseases like atopic dermatitis and bronchial asthma.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure JP2025080194_04062026_PF_FP_ABST
Abstract
The present invention relates to compounds of formula (I) with STAT6 inhibitory activity for use in methods of treatment of inflammatory or allergic diseases, such as e.g. atopic dermatitis.
Need to check novelty before this filing date? Find Prior Art